Ltr Pharma Fpo has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from LTR Pharma
- Final Patients dosed in SPONTAN pivotal study
- First patients dosed in SPONTAN pivotal study
- Recruitment commences for SPONTAN Clinical Study
- SPONTAN Achieves Key Manufacturing Validation
- Response to ASX Query Letter
Later from LTR Pharma
- Suspension from Quotation
- Reinstatement to quotation
- SPONTAN achieves positive clinical study results
- LTR Pharma completes A$10.5 million placement
- SPONTAN prescribed to First Patient Under TGA
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma